Abstracts tagged "ANCA"

Abstract Number: 1551 • ACR Convergence 2023
Measurement of Sinonasal Disease Activity in Granulomatosis with Polyangiitis
Roger Yang¹, Ellen Romich², Shubhasree Banerjee³, Naomi Amudala³, Peter Merkel³, Joshua Baker³ and Rennie Rhee³, ¹University of Pennsylvania, Montréal, QC, Canada, ²Hospital of the University of Pennsylvania, Media, PA, ³University of Pennsylvania, Philadelphia, PA
Background/Purpose: In granulomatosis with polyangiitis (GPA), sinonasal inflammation can be severe and significantly impact quality of life. Little is known about the most effective local…
Abstract Number: 1863 • ACR Convergence 2023
Immune-mediated Hypertrophic Pachymeningitis: Focusing on the Localization and Volume of Thickened Dura Mater Lesion
Yasuhiro Shimojima¹, Junji Ikeda² and Yoshiki Sekijima¹, ¹Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan, ²Department of Medicine (Neurologu and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan
Background/Purpose: Hypertrophic pachymeningitis (HP) is a rare inflammatory neurological disorder characterized by the thickened dura mater with extensive tissue fibrosis and immune-mediated inflammation. Notably, headaches…
Abstract Number: 2375 • ACR Convergence 2023
Clinical Characteristics of ANCA-associated Vasculitis with High Levels of Serum Interleukin 7
Shoichi Fukui¹, Haruna Matsuo², Kanako Kojima³, Shota Kurushima¹, Tohru Michitsuji⁴, Yoshika Tsuji⁵, Toshimasa Shimizu³, Masataka Umeda³, Remi Sumiyoshi⁵, Takashi Igawa¹, Tomohiro Koga⁵, Shin-ya Kawashiri¹, Naoki Iwamoto¹, Tomoki Origuchi¹ and Atsushi Kawakami¹, ¹Nagasaki University, Nagasaki, Japan, ²Nagasaki University, Nagasaki City, Japan, ³Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁴Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Medical Sciences, Nagasaki, Japan, ⁵Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University, Nagasaki, Japan
Background/Purpose: Interleukin 7 (IL-7) is a hematopoietic growth factor produced by stromal cells in the bone marrow and thymus, which is indispensable in maintaining immune…
Abstract Number: 2381 • ACR Convergence 2023
ANCA-associated Vasculitis and Renal Disease in a Multidisciplinary Outpatient Clinic in Northern Spain
Salma Al Fazazi¹, Fabricio Benavides², Vanesa Calvo Río³, maria rodriguez Vidriales², clara escagedo Cagigas², monica renuncio garcia², luis martin penagos⁴ and Ricardo Blanco⁵, ¹Hospital Universitario Puerta Del Mar, Cádiz, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Valdecilla Hospital, Santander, Spain, ⁴Division of Nephrology, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-DIVAL, Santander, Spain, ⁵Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: The severity of clinical features and outcomes in previous series of patients reported with renal disease related to ANCA-associated vasculitis (AAV) vary greatly, probably…
Abstract Number: 2383 • ACR Convergence 2023
Clinical Characteristics, Treatment Patterns, and Clinical Outcomes in Patients with Dual Positive Anti-Neutrophil Cytoplasmic Antibody and Anti-Glomerular Basement Membrane Antibody: A Single Center Experience
Zaina Shahid, Michael Lucke and Swati Arora, Allegheny Health Network, Pittsburgh, PA
Background/Purpose: Knowledge of disease characteristics and long-term outcomes of dual-positive patients (DPP) exhibiting anti-neutrophil cytoplasmic antibodies (ANCA) and anti-glomerular basement membrane (GBM) antibodies is limited…
Abstract Number: 2491 • ACR Convergence 2023
Alignment Between the Novel 2022 ACR/EULAR Classification Criteria for ANCA-associated Vasculitis (AAV), Clinical Diagnosis and Organ Manifestations in a European AAV Cohort
Stefan Krämer¹, Thomas Rauen¹, Kristian Vogt¹, Teresa Anslinger¹, Martin Busch², Tobias Schmitt³, Raoul Bergner⁴, Sebastian Mosberger⁴ and Thomas Neumann⁵, ¹RWTH, University Hospital Aachen, Department of Nephrology and Rheumatology, Aachen, Germany, ²University Hospital Jena, Friedrich-Schiller University, Department of Internal Mediciine III, Jena, Germany, ³University Hospital Jena, Friedrich Schiller University, Department of Nephrology, Jena, Germany, ⁴Municipal Hospital Ludwigshafen, Department of Internal Medicine A, Nephrology and Rheumatology, Ludwigshafen, Germany, ⁵Cantonal Hospital St. Gallen, Department of Rheumatology, St. Gallen, Switzerland
Background/Purpose: In 2022, ACR and EULAR proposed new classification criteria for granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) based on a numerical item scoring…
Abstract Number: 0442 • ACR Convergence 2022
Induction Therapy Patterns for Severe ANCA-associated Vasculitis Differ Based on Physician Specialty, Expertise, and Practice Setting: An International Survey
Lilian Xu¹, Faten Aqeel¹, Ojaswi Tomar², Tingting Li² and Duvuru Geetha¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Washington University in St. Louis School of Medicine, St. Louis, MO
Background/Purpose: Therapies for ANCA-associated vasculitis (AAV) have evolved over the last 3 decades. In light of new data on plasma exchange (PLEX) and glucocorticoid (GC)…
Abstract Number: 1948 • ACR Convergence 2022
Clinical Characteristics and Outcomes of Pediatric ANCA-Associated Vasculitis Patients: Single-Center Inception Cohort
Hyun Ho Lee¹, Lauren Blazek² and Eveline Wu³, ¹The University of North Carolina Chapel Hill, Chapel Hill, NC, ²UNC Kidney Center, The University of North Carolina Chapel Hill, Chapel Hill, NC, ³University of North Carolina, Chapel Hill, NC
Background/Purpose: ANCA associated vasculitis (AAV) is a chronic autoimmune disorder characterized by ANCA production and small vessel inflammation and necrosis. ANCA autoantigen targets include myeloperoxidase…
Abstract Number: 0443 • ACR Convergence 2022
Prognosis of Non-PR3 ANCA-Associated Vasculitis with Glomerulonephritis
Aurélien Chepy¹, Hélène Béhal², Alexandre Karras³, Xavier Puéchal⁴, Benjamin Terrier⁴, David Jayne⁵, Thomas Quéméneur⁶ and Mary-Jane Guerry⁷, ¹CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), Lille, France, ²University of Lille, CHU Lille, ULR 2694 - METRICS: Évaluation des Technologies de Santé et des Pratiques Médicales, Lille, France, ³HEGP, Paris, France, ⁴National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ⁵University of Cambridge, Cambridge, United Kingdom, ⁶Valenciennes Hospital, Valenciennes, France, ⁷Department of Nephrology, Centre Hospitalier de Valenciennes, Valenciennes., Valenciennes, France
Background/Purpose: Immunosuppressive treatments have improved the prognosis of anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV), transforming these formerly fatal diseases into chronic conditions, with periods of…
Abstract Number: 0450 • ACR Convergence 2022
Incidence of Solid and Hematologic Tumors in Patients with ANCA: A 10-year Retrospective Cohort Study
Enrico Brunetta¹, Giacomo Ramponi², marco folci², Maria De Santis³, Giacomo Maria Guidelli¹, Angela Ceribelli⁴, Nicoletta Luciano¹, Marta Caprioli⁵, Arianna Sonaglia¹ and Carlo Selmi⁶, ¹IRCCS Humanitas Research Hospital, Rheumatology and Clinical Immunology, Rozzano, Italy, ²IRCCS Humanitas Research Hospital, Internal Medicine, Rozzano, Italy, ³Humanitas University, IRCCS Humanitas Research Hospital, Rheumatology and Clinical Immunology, Pieve Emanuele, Italy, ⁴Humanitas Research Hospital, Humanitas University, Rozzano (MI) Italy, Borgo San Giacomo, Italy, ⁵IRCCS Humanitas Research Hospital, Rheumatology and Clinical Immunology, Pavia, Italy, ⁶IRCCS Humanitas Research Hospital, Humanitas University, Rozzano (MI), Italy, Rozzano, Italy
Background/Purpose: Serum antineutrophil cytoplasmic antibodies (ANCA) are significantly associated with the development of ANCA-associated vasculitides (AAV) but may also be detected in patients with other…
Abstract Number: 0457 • ACR Convergence 2022
A Systematic Literature Review Informing the 2022 Update of the EULAR Recommendations for the Management of ANCA-associated Vasculitis
Jan Schirmer¹, Beatriz Sanchez-Alamo², Sara Monti³, Bernhard Hellmich⁴, David Jayne⁵ and Gunnar Tomasson⁶, ¹University Medical Center Schleswig-Holstein, Kiel, Germany, ²Lund University, Skåne University Hospital, Lund, Sweden, ³Rheumatology, Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Pavia, Italy, ⁴Medius Kliniken, University of Tübingen, Kirchheim Teck, Germany, ⁵University of Cambridge, Cambridge, United Kingdom, ⁶Centre for Rheumatology Research, University Hospital Reykjavik, Reykjavik, Iceland
Background/Purpose: Since the publication of the 2016 European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of ANCA-associated vasculitis (AAV), the publication of…
Abstract Number: 0513 • ACR Convergence 2022
The Association Between Age of Diagnosis and Disease Characteristics and Damage in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Jessica Bloom¹, Kaci Pickett², Lori Silveira², David Cuthbertson³, Nader Khalidi⁴, Curry Koening⁵, Carol Langford⁶, Carol McAlear⁷, Paul Monach⁸, Larry Moreland¹, Christian Pagnoux⁹, Rennie Rhee¹⁰, Philip Seo¹¹, Ulrich Specks¹², Kenneth J. Warrington¹², Robert Fuhlbrigge¹ and Peter Merkel¹⁰, ¹University of Colorado, Denver, CO, ²University of Colorado Anschutz Medical Campus, Aurora, CO, ³University of South Florida, Tampa, FL, ⁴McMaster University, Hamilton, ON, Canada, ⁵University of Texas Dell Medical School, Austin, TX, ⁶Cleveland Clinic, Cleveland, OH, ⁷University of Pennsylvania, Philadelphia, ⁸VA Boston Healthcare System, Boston, MA, ⁹Mount Sinai Hospital, Toronto, ON, Canada, ¹⁰University of Pennsylvania, Philadelphia, PA, ¹¹Johns Hopkins University, Baltimore, MD, ¹²Mayo Clinic, Rochester, MN
Background/Purpose: Clinical characteristics and outcomes often differ between children and adults diagnosed with the same rheumatic condition; however, such comparative data is limited in ANCA-associated…
Abstract Number: 0526 • ACR Convergence 2022
Characteristics and Outcomes of Participants with and Without Diffuse Alveolar Hemorrhage in the Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis (PEXIVAS) Trial
Lynn Fussner¹, Luis Felipe Flores-Suarez², Rodrigo Cartin-Ceba³, Ulrich Specks³, P. Gerard Cox⁴, David Jayne⁵, Peter Merkel⁶ and Michael Walsh⁴, ¹The Ohio State University, Columbus, OH, ²Instituto Nacional de Enfermedades Respiratorias, Ciudad de México, Mexico, ³Mayo Clinic, Rochester, MN, ⁴McMaster University, Hamilton, ON, Canada, ⁵University of Cambridge, Cambridge, United Kingdom, ⁶University of Pennsylvania, Philadelphia, PA
Background/Purpose: Diffuse alveolar hemorrhage (DAH) is a potentially life-threatening manifestation of ANCA-associated vasculitis (AAV). Studies describing patients with DAH in AAV have typically been small…
Abstract Number: 1072 • ACR Convergence 2022
Efficacy and Safety Assessment of a Rituximab Biosimilar in Patients with Granulomatosis with Polyangiitis (GPA)
Adil Vural¹, Komal Mushtaq¹, Chao Zhang¹, Mahmoud Alwakeel¹, Vickie Sayles¹, Kristine Duly², Carol Langford¹ and Rula Hajj-Ali³, ¹Cleveland Clinic, Cleveland, OH, ²Cleveland Clinic, Fairview Park, OH, ³Cleveland Clinic, Hunting Valley, OH
Background/Purpose: A biosimilar is a medication that is highly similar to a biologic agent that is already approved by a regulatory organization. Considering the share…
Abstract Number: 1073 • ACR Convergence 2022
Analysis of Clinical Outcomes in ANCA-associated Vasculitis Treated with Rituximab: Eighty Years a Single Center Experience in Japan
Soko Kawashima¹, Mitsumasa Kishimoto², Yoshinori Komagata³ and Shinya kaname⁴, ¹Kyorin University, Mitaka Tokyo, Japan, ²Kyorin University School of Medicine, Yokohama, Japan, ³Kyorin University School of Medicine, Tokyo, Japan, ⁴Kyorin University, Tokyo, Japan
Background/Purpose: Contrary to many Western countries, MPO-ANCA-associated vasculitis (MPO-AAV) is dominant in Japan. The therapeutic response to rituximab (RTX) may differ. Therefore, we conducted a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].